Clinical and demographic features associated with infections with extended-spectrum beta-lactamase–producing *Escherichia coli* in a health system in Maine, 2017

Eugene W. Liu MD1, Sarah N. Buss PhD2, Jennifer L. Trumbo MPH3 and Tina M. Temples MPH3

Abstract

In this case–control study, we identified receipt of β-lactam antibiotics and older age as independently associated with increased infection risk with ESBL-producing *Escherichia coli* among residents aged 20–88 years in a rural Maine hospital system where the infection prevalence of antibiotic-resistant *E. coli* is low.

Concise Communication

Emergence of multidrug-resistant bacteria is thought to be associated with misuse of antibiotics. One major set of resistance genes are extended-spectrum β-lactamases (ESBLs), which produce enzymes hydrolyzing the β-lactam ring, and are commonly found in *Escherichia coli*. Prior studies have identified various risk factors for ESBL-producing bacterial infections: a history of carbapenem-resistant colonization/infection, recent international hospitalization,1 presence of a urinary catheter, diabetes, hospitalization in the past year,2 exposure to health care, previous antimicrobial use,3 surgery, and proton pump inhibitor (PPI) use.4 In Maine, the prevalence of drug-resistant *E. coli* is low (2.7% vs 7.5% nationwide).5 In this study, we investigated risk factors for ESBL-producing *E. coli* infections at Eastern Maine Medical Center (EMMC), a tertiary hospital, and in 4 affiliated community hospitals and outpatient clinics serving >40% of the Maine population in its rural central and northeastern regions. In this rural setting, we hypothesized that the risk of drug-resistant infection is low due to low levels of exposure to healthcare settings or antibiotics. Understanding factors contributing to a lower prevalence of ESBL-producing *E. coli* in Maine may inform efforts to prevent emergence of antibiotic-resistant bacteria.

Methods

Study participants were identified from laboratory reports: residents of Maine aged 20–88 years with culture specimens in which *E. coli* was isolated during 2017. Individuals aged >88 years were excluded to prevent personal identification. Case patients were defined as patients with at least 1 *E. coli* isolate resistant to ceftriaxone (thus presumed to produce an ESBL). Control patients were those with *E. coli* isolates that were all susceptible to ceftriaxone.

Data elements of sex at birth, race, age, and ZIP code to determine residence in a Health Resources and Services Administration defined medically underserved area (MUA)6 were extracted from the Northern Light electronic medical record. For each study participant, an isolate of interest was determined, defined as the first ceftriaxone-resistant *E. coli* isolate in cases and the first ceftriaxone-susceptible isolate in controls. For each isolate of interest and corresponding specimen collection date, we extracted data on antibiotics and PPIs received in the prior 6 months (180 days), specimen type, number of primary care visits and hospitalizations of each subject in the prior 12 months, and associated diagnosis codes.

Analyses were performed using R statistical software (R Foundation for Statistical Computing, Vienna, Austria). We calculated Charlson comorbidity scores from diagnosis codes using the comorbidity package.7,8 We performed logistic regression using the survival package9,10 first by single factors. Factors with significant odds ratios on simple logistic regression were used in multiple logistic regression with bidirectional stepwise variable selection by the Akaike Information Criterion to identify independent risk factors.

This study was approved by the EMMC Institutional Review Board with an exempt determination for which consent is not required, wherein the use of protected health information involves no more than a minimal risk to the privacy of individuals and could not practically be conducted without a waiver and use of protected health information.

Results

Demographic features associated with infection

We identified 60 case patients (6%) and 1,017 controls (94%) (Table 1). Male sex (OR, 1.96; 95% confidence interval [CI],
1.42–4.04) and older age (OR, 1.03; 95% CI, 1.02–1.05) were associated with infection with an ESBL-producing E. coli on simple logistic regression. Race was not associated with infection, with 97% of both case patients and controls identifying as white. Residence in a MUA (OR, 0.56; 95% CI, 0.33–0.95) was negatively associated with infection.

Clinical predictors of infection

Most E. coli isolates of interest in both cases and controls were from urine (97% of cases, 96% of controls) (Table 1). No isolates from other sources were associated with infection compared to isolates from the urine. The number of hospitalizations was associated with infection (OR, 1.29; 95% CI, 1.08–1.54), but not the number of primary care visits. Weighted Charlson comorbidity score (OR, 1.25; 95% CI, 1.15–1.37) and receipt of PPIs (OR, 3.00; 95% CI, 1.64–5.49) were also associated with infection.

Antibiotic usage associated with infection

Receipt of any β-lactam in the 6 months prior to collection of an E. coli isolate of interest was associated with infection (OR, 5.70; 95% CI, 3.33–9.76) (Supplementary Table 2 online). Within this class of antibiotics, multiple β-lactam antibiotics were associated

| Table 1. Associations Between Demographic and Clinical Features of Patients and Infection With an Extended-Spectrum β-Lactamase–Producing E. coli Estimated With Simple Logistic Regression Models in a Case–Control Study—Maine, 2017 |
| --- |
| **Factor** | % of Cases | No. (N=60) | % of Controls | No. (N=1,017) | Odds Ratio (95% Confidence Interval) |
| **Sex** |  |  |  |  |  |
| Female | 75 (45) | 85 (869) | Reference |
| Male | 25 (15) | 15 (148) | 1.96 (1.42–4.04)** |
| **Age** |  |  |  |  | 1.03 (1.02–1.05)***ab |
| **Race** |  |  |  |  |  |
| American Indian/Alaska Native | 0 (0) | 1 (9) | NA |
| Asian | 2 (1) | 1 (8) | 2.13 (0.26–17.31) |
| Black or African American | 2 (1) | 0 (3) | 5.68 (0.58–55.44) |
| Multiple | 0 (0) | 0 (1) | NA |
| Native Hawaiian or Pacific Islander | 0 (0) | 0 (3) | NA |
| Other | 0 (0) | 0 (4) | NA |
| Elected not to answer | 0 (0) | 0 (1) | NA |
| White | 97 (58) | 97 (988) | Reference |
| **Residence in a medically underserved area** | 53 (32) | 67 (682) | 0.56 (0.33–0.95)** |
| **Specimen type** |  |  |  |  |  |
| Abdomen | 0 (0) | 1 (8) | NA |
| Blood | 3 (2) | 2 (18) | 1.87 (0.42–8.24) |
| Ear | 0 (0) | 0 (1) | NA |
| Extremity | 0 (0) | 0 (5) | NA |
| Not specified | 0 (0) | 0 (1) | NA |
| Pelvis | 0 (0) | 0 (4) | NA |
| Sinus | 0 (0) | 0 (1) | NA |
| Sputum | 0 (0) | 0 (2) | NA |
| Urine | 97 (58) | 96 (975) | Reference |
| Wound | 0 (0) | 0 (2) | NA |
| **Primary care visits** | (60) | (1017) | 1.00 (0.93–1.08) |
| **Hospitalizations** | (60) | (1017) | 1.29 (1.08–1.54)*** |
| **Weighted Charlson comorbidity score** | (57) | (966) | 1.25 (1.15–1.37)*** |
| **Receipt of proton pump inhibitors** | 27 (16) | 11 (110) | 3.00 (1.64–5.49)*** |

**P < .001; **P < .01; *P < .05.

*bCovariate included in the final multiple logistic regression model by bidirectional stepwise variable selection.

*bCovariate with significant association with infection with an ESBL-producing E. coli isolate in the final multiple logistic regression model.
with infection: piperacillin/tazobactam, cefazolin, ceftriaxone, and cefpodoxime. Receipt of azithromycin (OR, 4.77; 95% CI, 1.53–14.85) was also associated with infection.

**Independent risk factors for infection**

To identify independent risk factors, we performed multiple logistic regression with bidirectional stepwise variable selection on covariates associated with infection on simple logistic regression: sex, age, MUA residence, number of hospitalizations, weighted Charlson comorbidity score, receipt of PPIs, β-lactam antibiotics, and azithromycin. Bidirectional stepwise regression indicated that age, MUA residence, and receipt of β-lactam antibiotics should be included in our multiple logistic model. In this model, age (OR, 1.02; 95% CI, 1.01–1.04) and receipt of a β-lactam antibiotic (OR, 4.63; 95% CI, 2.57–8.32) were associated with infection, whereas MUA residence (OR, 0.60; 95% CI, 0.34–1.04) was not (Table 2).

**Discussion**

In this study, we identified receipt of β-lactam antibiotics and age as independent risk factors for infection with an ESBL-producing *E. coli* isolate in a hospital system in rural Maine in 2017. This association of receipt of β-lactams and infection is consistent with the selective pressure that β-lactams apply on *E. coli* variants, allowing ESBL-producing *E. coli* to predominate and cause infection. The association with age may be a marker for past exposure to β-lactam antibiotics or nosocomial infection with ESBL-producing *E. coli* as we only examined antibiotic exposures 6 months prior to the collection date of the isolate of interest. Recent receipt of β-lactam antibiotics (within 6 months) may have selected out archived ESBL-producing *E. coli* variants, the numbers of which may be correlated with age.

Receipt of azithromycin, a non-β-lactam, was associated with infection on simple logistic regression, but not independently, and may be due to the practice of using azithromycin for empiric antibiotic coverage with β-lactam antibiotics. Similarly, the association seen with receipt of PPIs only on simple logistic regression may be due to their use as prophylaxis against stress ulcers during hospitalizations.

With respect to the degree of exposure to healthcare, although we noted an association between infection and the number of hospitalizations and Charlson comorbidity scores, and a negative association with MUA residence on simple logistic regression, none of these factors were independently associated with infection. This finding suggests confounding with receipt of β-lactam antibiotics.

This study has several limitations. We examined receipt of antibiotics over 6 months; thus, the effect of remote receipt of antibiotics is unknown. The degree to which age interacts with receipt of β-lactams also remains unclear. Furthermore, we did not account for asymptomatic carriers of ESBL-producing *E. coli* nor for treatments outside the Northern Light Health System. The mechanisms of resistance to ceftriaxone of *E. coli* isolates are unknown in this study; presumed ESBL production could arise from plasmid or chromosome mediated genes. Finally, we were unable to provide direct evidence to explain the overall decreased prevalence of drug-resistant *E. coli* in Maine.

Despite the limitations of this study, we identified receipt of β-lactams and age as independent risk factors associated with infection with ESBL-producing *E. coli*. The association of β-lactam use and ESBL-producing *E. coli* highlights the importance of antimicrobial stewardship to prevent further emergence of antibiotic-resistant bacteria.

**Supplementary material.** To view supplementary material for this article, please visit https://doi.org/10.1017/ash.2021.169

**Acknowledgments.** Valerie Torske from Northern Light Health Information Services Integration & Data Management assisted with data extraction from the Northern Light EMR. Prashant Mittal, Clinical Assistant Professor at the University of New Hampshire, provided statistical consultation. The findings and conclusions in this report are those of the authors and do not necessarily represent the view of Northern Light Eastern Maine Medical Center nor the Northern Light Health System.

**Financial support.** This work was supported by the Northern Light Eastern Maine Medical Center, Bangor, Maine.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**References**

1. Goodman KE, Lessler J, Cosgrove SE, et al. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase–producing organism. Clin Infect Dis 2016;63:896–903.
2. Park YS, Adams-Haduch JM, Shutt KA, et al. Clinical and microbiologic characteristics of cephalosporin-resistant *Escherichia coli* at three centers in the United States. Antimicrob Agents Chemother 2012;56:1870–1876.
3. Kang CI, Wi YM, Lee MY, et al. Epidemiology and risk factors of community-onset infections caused by extended-spectrum beta-lactamase–producing *Escherichia coli* strains. J Clin Microbiol 2012;50:312–317.
4. Sogaard M, Heide-Jorgensen U, Vandenbroucke JP, Schonheyder HC, Vandenbroucke-Grauls CMJE. Risk factors for extended-spectrum beta-lactamase–producing *Escherichia coli* urinary tract infection in the community in Denmark: a case–control study. Clin Microbiol Infect 2017;23:952–960.
5. CDC Antibiotic Resistance Patient Safety Atlas, 2017. Centers for Disease Control and Prevention website. https://gis.cdc.gov/grasp/PSA/MapView.html. Published 2017. Accessed May 8, 2019.
6. Shortage areas. Health Resources and Services Administration website. https://data.hrsa.gov/topics/health-workforce/shortage-areas. Accessed February 28, 2021.
7. Gasparini A. Comorbidity: an R package for computing comorbidity scores. 2018;3:648.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
9. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
10. Therneau T. A Package for survival analysis in R. CRAN.R Project website. https://CRAN.R-project.org/package=survival. Published 2020. Accessed June 7, 2020.